Last updated on February 2018

A Study of 2nd-line FOLFIRI Bevacizumab vs. Irinotecan Bevacizumab in mCRC


Brief description of study

The primary purpose of this study is to determine the non-inferiority of overall survival FOLFIRI with or without Bevacizumab compared with Irinotecan (CPT-11) with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.

Detailed Study Description

Primary endpoint: Overall survival (OS), Secondary endpoints: Progression-free survival (PFS), Time to treatment failure (TTF), Overall response rate (ORR),Disease Control Rate (DCR), Safety.

Clinical Study Identifier: NCT03303495

Find a site near you

Start Over